NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









General Proximity

General Proximity

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.generalproximity.bio/

Last Round

Strategic

May 4, 2026

Total Funding Raised

$16M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

General Proximity is a biotechnology company that develops next-generation induced-proximity medicines using its proprietary OmniTAC platform to target previously undruggable proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

targeted protein degradationTPDdrug discoveryOmniTACbiotech platformoncology researchundruggable proteinsinduced proximitycomputational biologyprotein degraderspharma partnershipsdrug discovery platformdegradomicsmolecular glueproteolysis targeting chimeraPROTAC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

General Proximity Comps

Public and private peers based on sector, stage, and business model.

General Proximity comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

General Proximity Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMay 4, 2026
SeedJan 3, 2025

Key People

Founding team and executive leadership

Armand Cognetta

Founder And CEO

Founding Team

General Proximity Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    Raised capital from Daewoong Pharmaceutical and FreeMind Group.

  • Nov 12, 2025

    Partnered with Daiichi Sankyo to apply OmniTAC discovery platform to oncology programs.

General Proximity Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

General Proximity Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about General Proximity's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range22
Year Founded2019
Last FundingMay 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.